All images in this section are for illustration purposes only. Not actual patients or caregivers.

Chronic Sialorrhea in Pediatrics

XEOMIN Patients (Aged 6–17 Years) Had Significant and Sustained
Reductions in Unstimulated Salivary Flow Rate (uSFR)1*

Chart showing significant sustained reductions in unstimulated salivary flow rate.

Pivotal Trial Design

Dose-response Study of XEOMIN in Children and
Adolescent Patients (Aged 2–17 years) with Chronic Sialorrhea1

Clinical trial of XEOMIN® in pediatric patients with chronic sialorrhea.

*Children aged 2–5 years were treated only with XEOMIN (open-label), and these patients were not included in calculation of the co-primary endpoints.

Reference

  1. XEOMIN®[Package insert]. Raleigh, NC: Merz Pharmaceuticals, LLC; 2021.
XEOMIN is the first and only FDA-approved neuromodulator
for pediatric patients with chronic sialorrhea

XEOMIN Patients (Aged 6–17 Years) Had Clinically Meaningful
Improvement in Carer’s Global Impression of Change Scale (GICS)1

Chart showing improvement in carers' Global Impression of Change Scale (GICS) ratings.

XEOMIN Patients (Aged 6–17 Years)
Had Sustained Improvements in GICS Scores1

Chart showing sustained improvements in GICS score over time.

XEOMIN Patients, Aged 2–5 Years, Showed Similar Improvement in
Caregiver GICS Scores vs Patients Aged 6–17 Years1

Chart showing similar improvements in caregiver GICS scores in patients aged 2 to 5 years old and patients aged 6 to 17 years old.

Children aged 2–5 years were treated only with XEOMIN (open-label), and these patients
were not included in calculation of the co-primary endpoints.

Reference

  1. XEOMIN® [Package insert]. Raleigh, NC: Merz Pharmaceuticals, LLC; 2021.